FIELD: pharmacology.
SUBSTANCE: invention can be used for application of N-succinyl-L-glutamyl-L-lysine amide as an agent having anti-angiogenic activity.
EFFECT: invention suppresses pathological neoangiogenesis.
2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTANCE WITH ANGIOGENIC ACTIVITY | 2013 |
|
RU2613184C2 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR PARENTERAL APPLICATION ON BASIS OF HEXAMETHYLENEDIAMINE BIS-(N-MONOSUCCINYL-L-GLUTAMIL-L-LYSINE) IN LYOPHILIZED DOSAGE FORM | 2017 |
|
RU2678203C2 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR ORAL ADMINISTRATION BASED ON HEXAMETHYLENE AMIDE BIS-(N-MONOSUCCINYL-1-GLUTAMYL-L-LYSINE) (VERSIONS), MADE IN FORM OF A TABLET DISPERSIBLE IN THE ORAL CAVITY | 2018 |
|
RU2740754C1 |
| DRUG PREPARATION WITH ANTIARRHYTHMIC AND ANTIFIBRILLATORY ACTION | 2010 |
|
RU2477144C2 |
| SMALL MOLECULES WITH NGF-LIKE ACTIVITY AND ANTIDIABETIC PROPERTIES | 2013 |
|
RU2613314C2 |
| HEPATOPROTECTIVE EFFECT OF LOW MOLECULAR WEIGHT MIMETICS NGF | 2022 |
|
RU2790828C1 |
| METHOD FOR REGULATING NERVOUS FIBERS OF BLOOD VESSELS | 2018 |
|
RU2682160C2 |
| METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIA OF SKELETAL MUSCLE WITH RESVERATROL | 2012 |
|
RU2518965C1 |
| METHOD FOR PHARMACOLOGICAL CORRECTION OF EXPERIMENTAL CRITICAL SKELETAL MUSCLE ISCHEMIA WITH A COMBINATION OF SIMVASTATIN, UDENAFIL AND MONONUCLEAR FRACTION OF AUTOLOGOUS BONE MARROW | 2020 |
|
RU2726077C1 |
| METHOD OF TREATING CORONARY INSUFFICIENCY IN SIMULATED MYOCARDIAL ISCHEMIA | 2010 |
|
RU2444378C1 |
